Asymmetric dimethylarginine in end-stage renal disease patients: A biomarker modifiable by calcium blockade and angiotensin II antagonism?

14Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) is an emerging risk biomarker in cardiovascular and renal diseases. Apparently amlodipine and valsartan produce substantial reductions in the plasma concentration of this methylarginine in hemodialysis patients. These findings are of relevance for designing studies aimed at testing the etiologic relevance of ADMA to the high cardiovascular risk of ESRD.

Cite

CITATION STYLE

APA

Zoccali, C. (2006). Asymmetric dimethylarginine in end-stage renal disease patients: A biomarker modifiable by calcium blockade and angiotensin II antagonism? Kidney International. Nature Publishing Group. https://doi.org/10.1038/sj.ki.5001898

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free